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Abstract: Serum vitamin D levels negatively correlate with obesity and associated disorders such as
non-alcoholic steatohepatitis (NASH). However, the mechanisms linking low vitamin D (VD) status
to disease progression are not completely understood. In this study, we analyzed the effect of VD
treatment on NASH in mice. C57BL6/J mice were fed a high-fat/high-sugar diet (HFSD) containing
low amounts of VD for 16 weeks to induce obesity, NASH and liver fibrosis. The effects of preventive
and interventional VD treatment were studied on the level of liver histology and hepatic/intestinal
gene expression. Interestingly, preventive and to a lesser extent also interventional VD treatment
resulted in improvements of liver histology. This included a significant decrease of steatosis, a trend
towards lower non-alcoholic fatty liver disease (NAFLD) activity score and a slight non-significant
decrease of fibrosis in the preventive treatment group. In line with these changes, preventive
VD treatment reduced the hepatic expression of lipogenic, inflammatory and pro-fibrotic genes.
Notably, these beneficial effects occurred in conjunction with a reduction of intestinal inflammation.
Together, our observations suggest that timely initiation of VD supplementation (preventive vs.
interventional) is a critical determinant of treatment outcome in NASH. In the applied animal model,
the improvements of liver histology occurred in conjunction with reduced inflammation in the gut,
suggesting a potential relevance of vitamin D as a therapeutic agent acting on the gut–liver axis.
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) affects up to one-third of the Western world population,
where it has become an important public health problem. Representing the hepatic organ manifestation
of the metabolic syndrome, NAFLD is closely associated with obesity, hyperlipidemia and insulin
resistance. Histologically, NAFLD is defined by a spectrum of lesions starting with bland liver steatosis
without inflammation or fibrosis (i.e., NAFL). While liver steatosis per se is a rather benign state, it
can progress to non-alcoholic steatohepatitis (NASH) which involves hepatic inflammatory changes
and apoptosis leading to organ injury and fibrosis, and can ultimately advance to end-stage liver
disease including cirrhosis and cancer [1,2]. Due to the continuously increasing global burden of obesity,
NAFLD is currently among the most common causes of liver transplantation and is projected to become
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an even larger problem in the near future [3]. Since no pharmacological therapy has been approved for
the treatment of NAFLD so far, there is an urgent necessity to define pathophysiology-based strategies
of future interventions [4].
Vitamin D is an endocrine signaling molecule playing a major role in human health. To maintain
adequate physiological levels, vitamin D can be produced in the skin from a 7-dehydrocholesterol
precursor upon UV-B radiation or can be taken up with the diet. However, due to modern life-style
and the fact that only few foods contain high amounts of vitamin D, many people have vitamin D
levels that are below the recommended range. Especially in the obese population, vitamin D deficiency
(commonly defined as circulating 25-OH vitamin D levels of 30 ng/mL or less) is a very common
phenomenon [5–7]. In fact, a close correlation between body mass index (BMI) and 25-OH vitamin D
level has been described with −1.3 nmol/L vitamin D per 1 kg/m2 increase in BMI [8]. Importantly,
vitamin D deficiency is associated with certain metabolic complications and with the progression of
NAFLD. For example, low vitamin D levels are correlated with several markers of insulin resistance
such as plasma glucose, insulin, HOMA-IR and adiponectin in non-diabetic adults [9,10]. In individuals
with NAFLD, decreased 25-OH vitamin D levels can be found in close association to the histological
severity of hepatic steatosis, necro-inflammation and fibrosis [11]. Moreover, vitamin D deficiency
(defined as <20 ng/mL in this study) increases the likelihood of definitive NASH in US adult patients
with NAFLD [12]. Despite the wealth of these association studies, it is presently difficult to identify a
functional link between low serum vitamin D and disease progression as a causal relationship.
From a physiological point of view, the vitamin D that is produced in the skin or taken up from
the diet (i.e., vitamin D3/cholecalciferol) is undergoing 25-hydroxylation in the liver leading to 25-OH
vitamin D3 (calcidiol). 25-OH vitamin D represents the major form of the vitamin in the circulation.
Subsequently, 25-OH vitamin D is undergoing 1-hydroxylation in the kidney to be converted into its
biologically active form 1,25-dihydroxyvitamin D3 (i.e., calcitriol). Calcitriol is an endocrine signaling
molecule that binds to the vitamin D receptor (VDR, NR1I1), which serves as a ligand-activated
transcription factor to control the expression of a large spectrum of diverse target genes in various
tissues [13,14]. As one of the classical endocrine functions, calcitriol/VDR controls the uptake of
dietary calcium in the gut [15]. Besides that, more recent studies suggest that the activation of 25-OH
vitamin D to 1,25-dihydroxyvitamin D can also be carried out by certain immune cell types, implicating
a role of active vitamin D and VDR as local immuno-modulators [16].
In fact, a number of beneficial effects of vitamin D on metabolic organs including adipose tissue
and liver have been described in the context of obesity and chronic inflammatory disorders [17].
For example, vitamin D substitution in obese or insulin-resistant subjects leads to the amelioration
of insulin resistance without affecting insulin secretion [18,19]. Similarly, a therapeutic potential of
vitamin D has been suggested in NAFLD but the precise effects of high-dose vitamin D intervention
(beyond substitution) versus untreated 25-OH vitamin D deficiency has not been studied in detail.
The aim of the present study was to investigate the preventive and interventional effects of high-dose
vitamin D treatment in a dietary mouse model of obesity and vitamin D deficiency resembling the
human hepatic phenotype of fibrosing NASH.
2. Material and Methods
2.1. Animals and Diets
Mice were housed in groups of 5 animals on a 12 h light/dark schedule and had free access to food
and drinking water. Eight-week-old male C57BL/6J mice (Charles River, Sulzfeld, Germany) were
used for the study and were assigned to one of the following groups: “LFD” mice received a low-fat
control diet (LFD, E15051, Ssniff Spezialdiäten GmbH, Soest, Germany) containing 500 IU vitamin D3
per kg diet for 16 weeks. The “HFSD” group received a high-fat/high-sugar Surwit diet (59 kcal% from
fat, E15772, Ssniff Spezialdiäten GmbH, Soest, Germany) containing 500 U vitamin D3 per kg diet for
16 weeks. As this vitamin D3 content of 500 IU per kg diet is only half of the amount recommended by
Nutrients 2019, 11, 77 3 of 14
the National Research Council [20], this feeding regimen should cause a state of moderate vitamin D
deficiency. In the “HFSD + VD3 prevention” and “HFSD + VD3 intervention” groups, the vitamin D3
content of the HFSD was modified as follows. In the “HFSD + VD3 prevention” group, animals were
fed with HFSD containing a high dose of 10,000 IU vitamin D3 per kg diet for the entire duration of the
study (16 weeks). In contrast, the “HFSD + VD3 intervention” group received HFSD diet with 500 IU
vitamin D3 for 12 weeks and then switched to the HFSD containing 10,000 IU vitamin D3 for further
4 weeks (see experimental set-up in Figure 1A). Additionally, the drinking water of all three HFSD
groups was enriched with sucrose (18.9 g/L) and fructose (23.1 g/L). This dietary treatment (HFSD
combined with sucrose/fructose-enriched drinking water) has previously been shown to induce NASH
and fibrosis in mice after 16 weeks of feeding [21]. At the end of the study, samples were collected after
8–12 h of fasting. All animal experiments were performed with the approval of the local authorities
(Regierung von Unterfranken, Würzburg, Germany).
2.2. Serum 25-OH Vitamin D Levels
Serum vitamin D levels were determined with the 25-OH Vitamin D ELISA (REA300/96,
BioVendor, Kassel, Germany) according to the manufacturer‘s instructions. In addition to the four
experimental groups mentioned in the previous section, age-matched male C57BL/6J mice that were
fed with a standard lab chow (supplemented with 1000 IU vitamin D3/kg diet) were included in the
analysis in order to obtain normal vitamin D reference values.
2.3. Histological Analyses
Formalin-fixed and paraffin-embedded liver samples were sectioned and stained with either
haematoxylin and eosin (H&E) or Ladewig trichrome. Specimens were analyzed by a pathologist
blinded to the experimental groups (SK). Liver steatosis, inflammation, hepatocyte ballooning and
fibrosis were scored according to Kleiner et al. [22]. Using this method, individual scores for steatosis
(0–3), inflammation (0–3) and ballooning (0–2) were provided and were added up to determine the
NAFLD activity score (NAS) as a semi-quantitative measure of disease severity. Fibrosis was scored
separately from 0 to 4 with 0 indicating absence of fibrosis and 4 indicating liver cirrhosis. Images
were taken with a BZ-9000 microscope and processed with the BZ-II Analyzer software (Keyence,
Neu-Isenburg, Germany).
2.4. RNA Isolation and Gene Expression Analysis
Total RNA from liver and ileum samples was extracted with the Nucleo Spin RNA kit
(Machery-Nagel, Dueren, Germany) according to the manufacturer’s instructions. Reverse
transcription was carried out with the High-Capacity cDNA Reverse Transcription Kit (Thermo
Fisher Scientific, Dreieich, Germany). Gene expression was analyzed by quantitative PCR (qPCR) with
the SYBR Select Master Mix on a ViiA7 (Thermo Fisher Scientific, Dreieich, Germany). Relative mRNA
expression was calculated by the comparative ∆∆CT method. Normalization was done using Rplp0
and Vil1 as housekeeping genes for liver and intestinal samples, respectively.
2.5. Serum Endotoxin
Endotoxin concentrations in serum were measured as previously described [23]. In brief, a
commercially available endpoint limulus amebocyte lysate assay with a concentration range of
0.015–1.2 EU/mL (Charles River, Lyon, France) was used to determine bacterial endotoxin levels.
2.6. Lipopolysaccharide (LPS)-Binding Protein ELISA
Mouse LPS-binding protein (LBP) was measured in serum using a commercially available mouse
LBP ELISA (Hycult Biotech, Uden, The Netherlands) according to the manufacturer’s instructions.
The detection limit of the assay was 0.8 ng/mL.
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2.7. Statistical Analyses
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software Inc, San Diego,
CA, USA). Data was analyzed by the Mann–Whitney test. Statistically significant differences between
groups are indicated by asterisks: * P < 0.05, ** P < 0.01, and *** P < 0.001. Samples sizes were n = 9–10
per group except for the analysis serum vitamin D levels (n = 6–7 per group).
3. Results
3.1. Effects of Vitamin D Treatment on Metabolic Parameters and on Serum 25-OH Vitamin D Levels in
HFSD-Fed Mice
As expected, HFSD mice developed obesity characterized by significantly enhanced body weight
gain, increased liver weight and increased epididymal fat mass compared to LFD-fed animals
(Figure 1B–E). In addition, mice in the HFSD group showed elevated fasting blood glucose levels
indicative of reduced glucose tolerance and/or impaired insulin sensitivity (Figure 1F). Although
neither the preventive nor the interventional vitamin D treatment could fully counteract these
unbeneficial metabolic changes, a moderate but non-significant decrease of body weight, liver weight
and fat mass was noted in the preventive treatment group (Figure 1C–E).
Notably, both the LFD and the HFSD control groups (receiving 500 IU of vitamin D3 per kg diet
throughout the study) showed significantly decreased serum levels of 25-OH vitamin D compared to
age-matched mice that were fed standard chow not depleted for vitamin D (supplemented with 1000 IU
vitamin D3/kg diet) (Figure 1G). Moreover, both the preventive and the interventional high-dose
vitamin D treatments in the HFSD groups increased serum 25-OH vitamin D levels compared to the
vitamin D-depleted HFSD group (P < 0.001 and P = 0.07), leading to an almost complete normalization
at the end of the study. These data demonstrate that the applied vitamin D-depleted HFSD-feeding
model accurately resembles the metabolic state of hypovitaminosis D which is well recognized in the
majority of human patients with obesity and/or NAFLD.
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(HFSD + VD3 prevention) or week 12 (HFSD + VD3 intervention) onwards (see Material and 
Methods for further details). At the end of the study, general metabolic parameters were measured: 
(B, C) weight gain, (D) liver weight, (E) epididymal fat mass, (F) fasting blood glucose and (G) 
serum 25-OH vitamin D levels. Data in (B–F) represent mean +/- SEM derived from n = 9 for LFD 
and n = 10 for all the other groups. Data in (G) represent mean +/- SEM derived from n = 6 for LFD 
and n = 7 for all other groups. ## in (G) indicate P < 0.01 compared to chow-fed mice. 
3.2. Effects of Vitamin D Treatment on NAFLD Activity and Liver Fibrosis 
Liver histology was analyzed in tissue sections stained with H&E (Figure 2A) or Ladewig 
trichrome (Figure 2B). As expected, low vitamin D-treated HFSD-feeding induced significant 
increases in liver steatosis, inflammation and hepatocyte ballooning compared to the LFD-fed 
group (Figure 2C–E), resulting in the presence of definite NASH in the majority of these animals 
(median NAFLD activity score of 4; Figure 2F). In addition, liver fibrosis was present in 50% of the 
low vitamin D-treated HFSD-fed mice, which is in line with a previous report using a similar 
experimental set-up based on HFSD-feeding combined with sucrose/fructose-enriched drinking 
water [21]. 
With regard to the therapeutic effects of vitamin D, preventive treatment with 10,000 IU per kg 
diet caused a significant decrease of steatosis (Figure 2C) and slight but non-significant 
improvements of inflammation and ballooning (Figure 2D, E). Importantly, this resulted in a clear 
Figure 1. Effects of vitamin D treatment on general metabolic parameters in HFSD-fed mice.
(A) Experimental set-up. Male C57BL/6J mice received high-fat/high-sugar diet (HFSD) or low-fat
control diet (LFD) for 16 weeks. Vitamin D3 (VD3) treatment was either performed from week 0 (HFSD
+ VD3 prevention) or week 12 (HFSD + VD3 intervention) onwards (see Material and Methods for
further details). At the end of the study, general metabolic parameters were measured: (B,C) weight
gain, (D) liver weight, (E) epididymal fat mass, (F) fasting blood glucose and (G) serum 25-OH vitamin
D levels. Data in (B–F) represent mean ± SEM derived from n = 9 for LFD and n = 10 for all the other
groups. Data in (G) represent mean ± SEM derived from n = 6 for LFD and n = 7 for all other groups.
## in (G) indicate P < 0.01 compared to chow-fed mice.
3.2. Effects of Vitamin D Treatment on NAFLD Activity and Liver Fibrosis
Liver histology was analyzed in tissue sections stained with H&E (Figure 2A) or Ladewig
trichrome (Figure 2B). As expected, low vitamin D-treated HFSD-feeding induced significant
increases in liver steatosis, inflammation and hepatocyte ballooning compared to the LFD-fed group
(Figure 2C–E), resulting in the presence of definite NASH in the majority of these animals (median
NAFLD activity score of 4; Figure 2F). In addition, liver fibrosis was present in 50% of the low vitamin
D-treated HFSD-fed mice, which is in line with a previous report using a similar experimental set-up
based on HFSD-feeding combined with sucrose/fructose-enriched drinking water [21].
With regard to the therapeutic effects of vitamin D, preventive treatment with 10,000 IU per kg
diet caused a significant decrease of steatosis (Figure 2C) and slight but non-significant improvements
of inflammation and ballooning (Figure 2D,E). Importantly, this resulted in a clear trend towards
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lowered overall NAFLD activity (Figure 2F, P = 0.09). In addition, a slight non-significant decrease of
liver fibrosis was observed in the preventive treatment group (Figure 2G). Similar beneficial effects on
liver histology could also be found after interventional vitamin D treatment, however, these effects
were less pronounced and did not reach significance. This indicates that timely onset of vitamin D
treatment is critical for a relevant improvement of NASH in the applied animal model.
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3.3. Vitamin D Treatment Reduces the Expression of Lipogenic, Inflammatory and Pro-Fibrotic Genes in the 
Liver of HFSD-Fed Mice 
In accordance with the induction of obesity and histologically defined NASH in the applied 
animal model, the expression of key genes involved in lipogenesis (Figure 3A–D), inflammation 
(Figure 3E–I), and fibrogenesis (Figure 3J–L) was increased in low vitamin D-treated HFSD-fed 
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Figure 2. Effects of preventive and interventional vitamin D treatment on liver histology and NAFLD
activity after 16 weeks of HFSD-feeding. Representative H&E-stained and trichrome-stained liver
sections are shown in (A) and (B), respectively (bars, 200 µm). The enlarged picture detail in (A) shows
an example of a ballooned hepatocyte. (C–G) Steatosis, inflammation, hepatocyte ballooning and
liver fibrosis were scored according to Kleiner et al. [22]. Data are presented as scatter and dot plots
with median. Sample sizes for all analyses shown in (C–G) were n = 9 for LFD and n = 10 for all the
other groups.
3.3. Vitamin D Treatment Reduces the Expression of Lipogenic, Inflammatory and Pro-Fibrotic Genes in the
Liver of HFSD-Fed Mice
In accordance with the induction of obesity and histologically defined NASH in the applied animal
model, the expression of key genes involved in lipogenesis (Figure 3A–D), inflammation (Figure 3E–I),
and fibrogenesis (Figure 3J–L) was increased in low vitamin D-treated HFSD-fed mice compared to LFD
controls. In line with the improvements of liver histology shown in Figure 2, the preventive vitamin D
treatment group showed significant reductions of the expression levels of certain disease marker genes.
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These genes included Mogat1 which encodes the lipogenic enzyme monoacylglycerol O-acyltransferase
1 (MGAT1) and Ccl2 encoding the pro-inflammatory chemokine monocyte chemoattractant protein 1
(MCP-1). In addition, the expression of other factors involved in lipogenesis (Srebf1 encoding sterol
regulatory element-binding protein 1) and inflammation (Itgax encoding the cell-surface protein Cd11c
and Tlr9 encoding Toll-like receptor 9) tended to be lower (P ≤ 0.1) in the preventive treatment group,
although these effects did not reach statistical significance. In comparison to the preventive treatment
arm, the effects of the interventional treatment with high-dose vitamin D were less pronounced for
most of the analyzed genes without statistical significance compared to the low vitamin D-treated
HFSD-fed group (with the exception of Tlr9).
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Figure 3. Effects of vitamin D treatment on hepatic gene expression after 16 weeks of HFSD-feeding.
Expression levels of lipogenic (A–D), inflammatory (E–I) and pro-fibrotic (J–L) genes were analyzed
by qPCR. Data represent mean ± SEM derived from n = 9 for LFD and n = 10 for all the other groups.
Relative gene expression was normalized to Rplp0 mRNA levels.
3.4. Effects of Vitamin D on the Intestinal Expression of Fgf15 and Hepatic Genes Involved in Bile
Acid Syn hesis
We aimed to obtain insights into the mechanisms that could underlie the beneficial effects of
high-dose vitamin D on HFSD-induced ob sity, liver histology and hepatic g ne xpression. Fibroblast
growth factor 15 (FGF15) is an intestine- eriv d hormone that re ul tes bile c d (BA) synth is i
the liver by d n-regulation of the rate-limiting e zyme CYP7A1 [24,25]. In addition to this, FGF19
(the uma ortholog of FGF15) has been suggested to improv adiposity and liver steatosis in obese
mouse models [26,27] d the m use Fgf15 gene has b en defined as a direct transcri tional target of
VDR [28]. Inter stingly, decreased levels of FGF19 have been reported in pati ts w th NAFLD and
other metabolic disorders, however, the underlying mechanisms are poorly defined [29]. Therefore,
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we investigated the expression of intestinal Fgf15 to analyze its potential contribution to the beneficial
effects of vitamin D described above. In fact, we observed a marked decrease of Fgf15 mRNA levels in
the ileum of HFSD-fed animals compared to LFD controls (Figure 4A). However, neither preventive
nor interventional treatment of HFSD-fed mice with high-dose vitamin D could restore ileal Fgf15
expression in this experimental set-up. This suggests that the intestinal VDR-FGF15 pathway is not the
primary metabolic mediator of the beneficial effects of vitamin D in the applied NASH mouse model.
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Figure 4. Expression of intestinal Fgf15 and hepatic genes involved in bile acid synthesis in vitamin
D-treated mice after 16 weeks of HFSD-feeding. (A) Expression of Fgf15 in the ileum and (B,C) Cyp7a1
and Cyp8b1 expression in the liver was analyzed by qPCR. Data represent mean ± SEM derived from
n = 9 for LFD and n = 10 for all the other groups. Relative mRNA expression was normalized to Vil1
(ileum) or Rplp0 (liver) transcript levels.
Besides alterations in serum FGF19 levels, human NAFLD is characterized by marked
changes of BA metabolism which have been suggested to contribute to disease activity by various
mechanisms [30–32]. Based on this, we analyzed the expression of genes involved in BA biosynthesis
in the livers of HFSD-fed mi e. In lin with a dysr gulation f BA metabolism in NAFLD, mRNA
levels of Cyp7a1 and Cyp8b1 were increased in HFSD-f d mice on low vitamin D compared to LFD
controls (Figure 4B,C). Interestingly, these inductions of Cyp7a1 nd Cyp8b1 were completely (Cyp8b1)
or partially (Cyp7a1; P = 0.1 co pared to HFSD) abrogated by preventive vitamin D tre tment.
This sugg ts that one mechanism underlying the beneficial effects of vit mi D in our NASH model
is based on nor alization of BA metabolism. Si ce these effects occurred in the absence of changes in
intestinal Fgf15, the repression of BA synthesis zymes by vit min D likely reflects a direct effect in
t liver. In line with this notion, Han and Chiang pr viously demonstrated that ligand-bound VDR
inhibits CYP7A1 expression in human hepatocytes by a direct transcriptional mechanism [33].
3.5. Vitamin D Attenuates the HFSD-Induced Up-Regulation of Inflammatory Markers in the Intestine
Obesity and metabolic disorders are generally associated with a chronic low-grade inflammation
in the gut and a partial impairment of the intestinal barrier, e.g., by down-regulation of tight junction
proteins, leading to increased intestinal permeability [34–36]. Increased permeability of the gut (also
termed “leaky gut”) can, in turn, lead to the translocation of bacterial metabolites such as LPS into
portal blood and the systemic circulation. By this mechanism, intestinal inflammation and impaired
intestinal barrier function can promote NASH and liver fibrogenesis in animal models and human
patients [37–40]. Based on this, serum levels of LPS and the endotoxemia surrogate marker LBP were
measured in blood samples of mice. However, neither LPS nor LBP was significantly increased in
HFSD-fed mice on low vitamin D as compared to lean LFD controls (Figure S1). This suggests that
increased translocation of LPS from the gut to the liver may not be the primary driving force of liver
inflammation in the applied experimental set-up.
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The expression of pro-inflammatory marker genes in the ileum of HFSD-fed mice was, however,
significantly changed. In line with previous studies, pro-inflammatory genes including Tlr4, Tnf and
Il1b were up-regulated in the ileum of low vitamin D-treated HFSD-fed animals in comparison to
LFD controls (Figure 5). Interestingly, this HFSD-induced intestinal inflammation was ameliorated
by vitamin D. This became evident by a complete normalization to LFD control levels for Tlr4
expression with both high-dose vitamin D prevention and intervention. In addition, Tnf and Il1b
expression levels clearly decreased in both vitamin D treatment groups without statistical significance.
These observations indicate that, in addition to the hepatic effects on BA homeostasis, vitamin D has
immunomodulatory effects in the gut that may contribute to the observed improvements of NASH by
reducing obesity-associated intestinal inflammation. The absence of increases in LPS or LBP serum
levels suggests that these inflammatory changes may not be necessarily accompanied by an impairment
of intestinal barrier function in our experimental model. As one possible explanation for this finding,
intestinally derived cytokines such as TNF of IL-1 may act as endocrine factors directly on hepatic
cells via the portal circulation to promote liver inflammation and fibrogenesis in NASH. However, this
aspect will need further validation in future studies.
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Figure 5. Intestinal expression of inflammatory marker genes in vitamin D-treated mice after 16 weeks
of HFSD-feeding. (A–C) Gene expression of Tlr4, Tnf and Il1b was measured by qPCR after reverse
transcription of total RNA extracted from the ileum. Data represent mean ± SEM derived from n = 9
for LFD and n = 10 for all the other groups. Relative mRNA expression was normalized to Vil1
transcript levels.
4. Discussion
The present study addresses the effects of preventive and interventional high-dose vitamin D
therapy in a dietary mouse model of obesity and vitamin D deficiency resembling fibrosing NASH
in humans. Major findings of the study were: (i) Preventive but not interventional treatment with
high-dose vitamin D showed a clear trend to counteract HFSD-induced body weight gain and adipose
tissue expansion. (ii) Increased 25-OH vitamin D serum levels in HFSD-fed animals were associated
with an improvement of liver steatosis, a trend towards reduced overall NASH activity and a slight
non-significant decrease of liver fibrosis. (iii) Preventive vitamin D treatment led to a variable degree
of reduction in expression levels of hepatic lipogenic genes, together with a decrease in inflammatory
and pro-fibrotic targets. (iv) A similar reversal of pro-inflammatory genes could be detected in the
intestine. (v) In the liver, the NAFLD-associated induction of genes involved in BA synthesis (Cyp7a1
and Cyp8b1) was markedly attenuated by vitamin D.
Previous preclinical studies in rodent models are partially controversial with regard to the
metabolic effects of vitamin D/VDR on obesity and NAFLD. While some studies have shown beneficial
outcomes [41–48], others suggest rather undesirable metabolic features of vitamin D and its receptor,
VDR, in certain animal models [49–51]. One explanation for the diversity of the results could be
related to considerable differences in study design. These, for example, include different doses and
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different biological forms of vitamin D that are provided (e.g., cholecalciferol, 1,25-dihydroxyvitamin
D, or pharmacological vitamin D analogues such as 1α-hydroxy-cholecalciferol or paricalcitol), as
well as different routes of their administration (diet/oral vs. injection). In this regard, it was an
important aspect of our study design that we used oral administration (via the diet) of vitamin D in the
chemical form of cholecalciferol. This treatment regimen would correspond to the use of vitamin D as
a nutritional supplement in humans, which is simple to use, cost-efficient and known to be generally
well-tolerated in doses as high as 4000–10,000 IU per day in clinical practice [52,53].
Among the previously published preclinical studies reporting an improvement of NAFLD by
vitamin D, Nakano and coworkers have investigated the impact of sunlight therapy on the progression
of NAFLD in rats fed a choline-deficient L-amino acid-defined (CDAA) diet [41]. Comparable to low
25-OH vitamin D levels reported in human NAFLD [11], 25-OH vitamin D and 1,25-(OH)2 vitamin D
serum levels decreased during CDAA feeding, however, it remained unclear whether this decrease
is due to the progression of NAFLD or simply reflecting a different dietary content of the CDAA
diet compared to standard chow. Consistent with our findings from the present study, Nakano et
al. reported that therapeutic intervention with the prodrug 1α-hydroxy-cholecalciferol ameliorated
histology as measured by a decreased hepatitis area.
Yin et al. investigated a nutritional rat model of high-fat diet (HFD) compared to a normal-fat
diet group with putative average vitamin D and supplemented the high-fat diet animals with
intraperitoneal injection of three different doses of 1,25-dihydroxyvitamin D3 [43]. Here, vitamin
D intervention prevented HFD-induced weight gain and hepatic steatosis, however, effects on
liver inflammation and fibrogenesis were not addressed in this study. Moreover, the effects of the
experimental diets on serum 25-OH vitamin D levels were not reported. Whether high-fat diet per se
causes hypovitaminosis D in this model remains unclear.
Another rat study by Roth et al. used a custom rodent high-fat and corn syrup (HFCS) diet with
a vitamin D content that was either normal (1000 IU vitamin D) or depleted (25 IU vitamin D) [42].
In this study, experimental vitamin D deficiency exacerbated the effects of HFCS on liver steatosis and
inflammation, thus resulting in increased disease activity measured by the NAFLD activity score [22].
However, significant liver fibrosis was not reported in this model and thus the effects of vitamin
D deficiency on fibrogenesis could not be evaluated in this study. Similar to that, Kong et al. used
high-fat diets, either devoid of vitamin D or containing a normal vitamin D content (1000 IU vitamin
D) [44]. For intervention, 1,25-dihydroxyvitamin D3 at a dose of 5 ng/g body weight was applied by
intramuscular injection twice a week. In this study, vitamin D deficiency caused increased NAFLD
severity while treatment with 1,25-dihydroxyvitamin D3 had an opposite effect. However, the scoring
system used to evaluate NASH and liver fibrosis in this study was apparently slightly different from
the histopathological standards presently used in most clinical trials [54].
The studies summarized above point to a beneficial role of vitamin D (and different vitamin D
analogs) on liver healthy in the context of obesity and metabolic disease. However, it is important to
note that not all of these studies addressed the therapeutic effect of vitamin D on bona fide NASH as
the progressive and clinically most relevant form of NAFLD. In our study, we used a mouse model that
was based on feeding of an HFSD and additional consumption of sucrose/fructose-enriched drinking
water. In line with a previous report [21], this led to the development of bona fide NASH (defined
by the presence of liver steatosis, inflammation and ballooning) in the majority of HFSD-fed control
mice as well as the occurrence of histo-pathologically detectable liver fibrosis in half of these animals.
This progressive histo-pathological phenotype is an important aspect of NAFLD animal models form
a clinical point of view [54], thus underlining the clinical relevance of our results.
Overall, our data and other preclinical reports point to a beneficial role of dietary vitamin D
supplementation in NASH as the progressive form of NAFLD. Moreover, our data imply that timely
initiation of this intervention may be crucial to prevent disease progression and point to an important
role of the gut as a primary target organ of the physiological and pharmacological actions of vitamin D.
A randomized placebo-controlled pilot study conducted by our group within the Swiss Association for
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the Study of the Liver (SASL) network has recently reported beneficial effects of vitamin D treatment
on serum ALT levels in patients with histologically defined NASH [55]. Together with the present
study, this warrants further investigation on the usefulness of vitamin D as a treatment option for
NASH and the underlying mechanisms in future clinical and preclinical trails.
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Figure S1: Effects of preventive and interventional vitamin D treatment on serum levels of lipopolysaccharide
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